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pite such advances, the impact of systemic therapies for advanced disease
as such, the prognosis for patients with NSCLC remains poor. Standard
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current management approaches. Tumor-treating fields (TTFields) are low-
frequency alternating electric fields that disrupt proper spindle microtubule
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ung cancer is the second most common
cancer and the leading cause of cancer-
related mortality in the United States.1 It
accounts for about 14% of all new cancers; more than
224,210 new cases are expected to be diagnosed in
the United States in 2014.1 Non-small cell lung cancer
(NSCLC) accounts for 80% to 85% of all lung cancer
cases. Most NSCLC patients present with advanced
stage III or IV disease.2 A common treatment modality
for advanced NSCLC is cytotoxic chemotherapy,
which is typically associated with a 20% to 35%
response rate and a median survival of approximately
10 to 12 months.3,4 For patients with advanced NSCLC
who progress after receiving a platinum-based chemo-
therapy regimen, second-line treatments offer only
modest survival benefit, often with significant toxic-
ity.5 Furthermore, patients with squamous histology
(which accounts for 25%–30% of all NSCLC cases)
do not typically respond to newer targeted therapies,S35-S41 S35
M. Giladi et alS36and managing these patients effectively remains an
area of high unmet need.
Tumor-treating fields (TTFields) are a novel treat-
ment modality delivered via continuous noninvasive
application of low-intensity, intermediate-frequency
alternating electric fields to the region of the tumor.6
TTFields have demonstrated effectiveness in the
treatment of solid tumors in vitro and in vivo.6–10
Several pilot clinical trials and larger randomized
studies in patients with solid tumors including glio-
blastoma have demonstrated the feasibility, safety,
and effectiveness of continuous TTFields application
in patients.7 Of note, recent phase I/II trial showed,
for the first time, preliminary efficacy and safety of
combining TTFields therapy with pemetrexed in
patients with stage IIIB/IV NSCLC following failure
of standard first-line therapy.11 This study demon-
strated a median progression-free survival (PFS) of 22
weeks and an encouraging in-field PFS (measured at
the site where TTFields were delivered to the lungs
and liver) of 28 weeks. Median overall survival was
13.8 months and 1-year survival was 57%, both of
which compared well to matched historical controls.
These results support the clinical activity of TTFields
therapy when added to chemotherapy in advanced
NSCLC, without incremental toxicity.
The present study attempts to further elucidate
the effects of TTFields in combination with different
chemotherapeutic agents on several NSCLC cell
lines, both in vitro and in vivo.MATERIALS AND METHODS
Tumor Cell Lines
We obtained four human NSCLC cell lines and two
murine cell lines from ATCC (American Type Culture
Collection, Rockville, MD). The NSCLC cell lines were
H1299 (adenocarcinoma), A549 (adenocarcinoma):
HTB-182 (squamous cell carcinoma [SCC]), and
HCC827 (adenocarcinoma, mutated in the epidermal
growth factor receptor [EGFR] tyrosine kinase
domain). The murine cell lines were LLC1 (Lewis lung
carcinoma 1) and KLN205 (SCC). All human cell line
cultures were maintained in Roswell Park Memorial
Institute (RPMI) medium supplemented with 10% fetal
calf serum (FCS). The LLC1 cell line was maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% FCS and 5% glutamine. The KLN205
cell line was maintained in MEM supplemented with
10% FCS. All cell lines were incubated in a humidified
incubator supplied with 5% CO2.
TTFields Application in Vitro
Methods for applying TTFields during the conduct
of in vitro studies have been described previously.7,9
In brief, two pairs of transducer arrays, insulatedwith a high dielectric constant ceramic (lead magne-
sium niobate–lead titanate), were positioned perpen-
dicularly in a Petri dish. The transducer arrays were
connected to a sinusoidal waveform generator at the
desired frequencies in the medium. The TTFields
changed direction by 901 every 250 ms. Temperature
was measured by a thermocouple (Omega Engineer-
ing, Stamford, CT) placed in the center of the dish.
TTFields were applied for 72 hours with or without
the chemotherapeutic agents paclitaxel (Sigma-
Aldrich, Rehovot, Israel), pemetrexed (Eli Lilly, Indian-
apolis, IN), cisplatin (Sigma-Aldrich), and erlotinib (LC
Laboratories, Woburn, MA).
Cell Viability and XTT Assay
Inhibition of tumor cell growth was analyzed by
quantitative determination of cell viability via standard
XTT methods (Cell Proliferation Kit; Biological Indus-
tries, Beit Haemek, Israel). The cell number was
determined and the relative number of viable cells at
the end of 72 hours of treatment was normalized to the
number of viable cells in untreated control.
Clonogenic Survival Assay
Cells treated for 72 hours with TTFields at 150
kHz frequency were subsequently harvested and
replated into 6-well tissue culture plates (300 cells/
well). Five to 10 days after seeding, colonies were
stained with 0.5% crystal violet, and the number of
colonies containing at least 50 cells were counted.
Survival fractions were calculated relative to control.
Efﬁcacy of Combination Treatments in Animal
Models
All animal studies were approved by the Novocure
Internal Animal Care committee in accordance with the
Technion-Israel Institute of Technology guidelines for
the care of laboratory animals. LLC1 cells (6103) were
mixed with 50% high-concentration growth-factor–
reduced Matrigel (BD Biosciences, Bedford, MA) and
were implanted in the left lung of 10-week-old C57Bl/6
mice (Harlan Laboratories, Jerusalem, Israel) 11 days
before treatment initiation using the same method
described by Onn et al.12 Mice were randomly grouped
(425 per group) before treatment with TTFields,
pemetrexed, cisplatin, paclitaxel, or TTFields combined
with these agents. Mice were treated for 6 days using
two-directional, 150-kHz TTFields at a field intensity of
1.86  0.67 V/cm RMS. Two pairs of insulated trans-
ducer arrays were placed on the depilated chest skin
overlying the lung area so that two perpendicular field
directions were delivered sequentially (1 second in
each direction) to the lungs. Treatment was applied for
at least 90% of the duration of the experiment. TTFields
parameters were continuously measured. The control
Figure 1. (A) Frequency-dependent effect of TTFields on
viability of lung cancer cells and inﬂuence of optimal
frequency on clonogenic potential. Effect of TTFields treat-
ment, administered in different frequencies, on cell viability of
various lung cancer cell lines (arrow indicates optimal fre-
quency). (B) Clonogenic potential of various lung cancer cell
lines after TTFields treatment at optimal frequency (150 kHz).
*Po.05,**Po.01, and ***Po.001 versus control group.
Improving chemotherapy treatment efﬁcacy in NSCLC using TTFields S37and chemotherapy-treated mice had sham transducer
arrays placed on their torsos; these arrays were
temperature-matched to the TTFields transducer
arrays.
Pemetrexed (1 mg/kg) and cisplatin (5 mg/kg)
both (as single bolus injection), and paclitaxel (20
mg/kg twice a day every 3 days) were administered
intraperitoneally on day 11 Eleven after tumor
implantation, and immediately before TTFields appli-
cation. Control mice received the relevant vehicles.
Initial tumor volume was evaluated from lung sam-
ples from mice euthanized on day 1 of treatment
initiation. Final tumor volume was assessed at nec-
ropsy (day 17 after tumor implantation) with Vernier
calipers using the formula width2  length  0.5.
The effects of TTFields on a rapidly growing,
syngeneic orthotopic tumor model of DBA/2 mice
injected with SCC were also examined. In brief,2104 murine SCC (KLN205) cells mixed with Matri-
gel were injected directly into the lungs of DBA/2
(Harlan) mice using the same method described for the
induction of LLC1 orthotopic tumors. Tumor uptake
was observed in 85%15% of the mice 3 weeks after
inoculation, but tumor progression was highly variable
(average volume, 24 mm3). Cells derived from DBA/2
lung tumors (KLN205-T1) were sub-cultured for more
than 10 generations. KLN205-T1 cells were then
thawed and cultured for 1 week before being used
for inoculation. Mouse left lung lobes injected with
5104 KLN205-T1 cells in 50% Matrigel demonstrated
rapid tumor growth, with a mean volume of 5113
mm3 13 days after injection. During the same period,
left lung lobe weight increased from 675 mg to
12319 mg. The observed tumor uptake was 80%
11%. Eleven days after tumor inoculation, the mice
were randomly grouped (412 per group) and treated
with TTFields, cisplatin, or their combination, as
described earlier.
Statistical Analysis
The statistical significance of differences were
assessed with one-way analysis of variance followed
by the Tukey range statistical test using GraphPad
Prism 6 (GraphPad Software, La Jolla, CA). Between-
groups differences were considered significant at
*Po.05, **Po.01, and ***Po.001. Data are expressed
as means and standard deviations of the mean.RESULTS AND DISCUSSION
TTFields Induce Frequency-Dependent
Reduction in Viability and Clonogenic
Capacity of NSCLC Cells In Vitro
The inhibitory effect of TTFields on tumor cell
growth is well established in various tumor cell lines
of different origins, but its specific impact on NSCLC
cells remains unclear. We investigated the effect of
TTFields in vitro, using four human NSCLC cell lines
(H1299, A549, HCC827, HTB-182) and two murine
cell lines (LLC1, KLN205). As the optimal TTFields
frequency required to disrupt cell culture viability
has previously been shown to be cell type–specific,
the cells were exposed to various frequencies
between 100 kHz and 240 kHz. TTFields therapy
was found to induce a frequency-dependent reduc-
tion in viability in all six cell lines, with a common
peak effective frequency at 150 kHz (Figure 1A).
Interestingly, similar efficacy was observed for cul-
tures of both adenocarcinoma and SCC histologies.
In subsequent experiments, the clonogenic potential
of single cells after 150-kHz TTFields treatment was
compared with that of untreated cells. TTFields
treatment was found to significantly impair the
colony-forming ability of all tested cell lines in
Figure 2. In vitro efﬁcacy of chemotherapy and TTFields. Dose–response plots of (A) pemetrexed alone and in
combination with TTFields on H1299 (adenocarcinoma) and LLC1 (Lewis lung carcinoma 1) cells; (B) cisplatin alone
and in combination with TTFields on H1299, LLC1, KLN205 (squamous cell carcinoma), and HTB-182 (squamous cell
carcinoma) cells; (C) paclitaxel alone and in combination with TTFields on H1299, LLC1, and HTB-182 cells; and
(D) erlotinib alone and in combination with TTFields on HCC827cells (adenocarcinoma, mutated in epidermal growth
factor receptor tyrosine kinase domain).
M. Giladi et alS38culture (Figure 1B). Treatment efficacy was found to
be positively correlated with TTFields intensities, as
previously described (data not shown).6,7 Together,
these in vitro findings support our previous obser-
vation, which suggest a cell type–specific optimal
effective frequency for TTFields therapy.TTFields Have an Additive Inhibitory Effect on
NSCLC Cell Proliferation When Combined
with Chemotherapeutic Agents In Vitro
Adjuvant TTFields have previously been shown to
increase the sensitivity of cancer cells to various
chemotherapeutic agents.9 To assess whether add-
ing TTFields to standard lung cancer chemotherapy
affects the responsiveness of NSCLC cells, we treatedthe cell lines with TTFields (1.75 V/cm RMS, 150
kHz) combined with pemetrexed (Figure 2A), cis-
platin (Figure 2B), and paclitaxel (Figure 2C) at
various concentrations. The antifolate pemetrexed
has demonstrated efficacy when used as a single
agent in second-line treatment of advanced non-SCC
NSCLC,13 in combination with cisplatin for first-line
therapy of advanced non-SCC NSCLC,14 and as
maintenance for this indication in patients whose
disease has not progressed after platinum-based first-
line chemotherapy.15 We investigated the effects of
combining TTFields with pemetrexed in various
NSCLC cell lines. The results (Figure 2A) showed
that adding TTFields to pemetrexed led to a decrease
in the number of viable cells for all tested concen-
trations in both H1299 and LLC1 cultures. These
Figure 3. In vivo effects of treatment combination of TTFields therapy and chemotherapy. Volume of LLC1 (Lewis lung
carcinoma 1) or KLN205-T1 (murine squamous cell carcinoma cells derived from DBA/2 mice lung tumors) tumors in mice
treated with (A) pemetrexed, (B,D) cisplatin, and (C) paclitaxel. *Po.05 and **Po.01versus control group.
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treatments. This effect is possibly explained by the
different stages of mitosis at which the two treat-
ment modalities putatively operate: Pemetrexed
inhibits three enzymes responsible for purine and
pyrimidine synthesis, thereby acting on the G1 and S
phases of the cell cycle,16 and TTFields therapy
predominantly acts on cells in the M phase.6,7,9
Although a platinum-based regimen is standard treat-
ment for patients with NSCLC, this approach may
have reached its plateau in terms of efficacy.17 The
combination of cisplatin, a commonly used first-line
NSCLC treatment, and TTFields showed a similar
pattern of augmented effect against NSCLC cell
viability, including in the SCC cell lines HTB-182
and KLN205 (Figure 2B). TTFields therapy in combi-
nation with paclitaxel had the same additive effect
and led to a decrease in the number of viable cells in
cultures of both adenocarcinoma and SCC cells
(Figure 2C). The combined effect of TTFields and
paclitaxel may be attributed to their shared cellular
targets. TTFields forces act on the dipole moment
of tubulin chains, leading to misalignment of mitotic
spindle filaments6 and paclitaxel stabilizes the link
between individual tubulin dimers, subsequently
increasing the length and average dipole moment
of the tubulin filaments. This, in turn, could increasethe TTFields-induced forces and sensitize cells to
TTFields. Interestingly, the KLN205 cell line, though
resisting high-concentration paclitaxel (inhibitory
concentration 50 [IC50]4100 nmol/L) (data not
shown), was sensitive to TTFields (Figures 1A, 2B),
suggesting TTFields also may be effective against
cells resistant to paclitaxel. NSCLC with activating
EGFR mutations is highly responsive to EGFR tyro-
sine kinase inhibitors, including erlotinib, an
approved agent for the treatment of locally advanced
or metastatic NSCLC. Compared with exposure to
erlotinib alone, the combination of TTFields and
erlotinib led to a significant reduction in HCC827
(EGFR mutant) cell viability (Figure 2D). Overall,
these results suggest that adding TTFields therapy to
systemic therapies including pemetrexed, cisplatin,
paclitaxel, and erlotinib may offer a viable approach
for improving clinical outcomes. Prospective studies
to investigate this hypothesis are warranted.TTFields Inhibit Tumor Growth in Autologous
NSCLC Mouse Models and Can Improve
Treatment Efﬁcacy When Combined with
Chemotherapy
We orthotopically implanted 6103 LLC1 cells
into the left lung of C57BL/6 mice and 5104
Figure 4. Distribution of TTFields within lungs. Finite-element mesh (three-dimensional mesh) simulations of distribution
of TTFields intensity within human chest model demonstrated effective distribution of ﬁelds applied by transducer arrays
with use of (A) anteroposterior layout (front transducer array) and (B) bilaterally (side transducer array).
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The results (Figures 3A–C) showed that LLC1 tumors
exposed to TTFields (1.860.67 V/cm RMS) in
combination with chemotherapy were smaller than
tumors treated with chemotherapy alone. Similar
results were observed for KLN205-T1 tumors
(Figure 3D). Interestingly, a significant decrease in
tumor volume was not observed in mice treated with
TTFields with average intensities below V/cm RMS,
demonstrating that TTFields are ineffective below a
certain threshold. Of note, the improved antitumor
activity of the combination of TTFields and chemo-
therapy also was apparent in autologous tumor
studies. These results are supportive of the in vitro
findings that suggest combining TTFields therapy
with chemotherapy may enhance treatment efficacy.
The combination may lead to an increased response
and also potentially may permit the use of a lower
dose of chemotherapy, thereby reducing systemic
toxicity.Effective-Intensity TTFields Can Be
Noninvasively Applied to the Lung
Parenchyma
To calculate the TTFields intensity required to
effectively alter treatment outcomes in larger organ-
isms, we performed two types of studies: finite-
element mesh (FEM) simulations of the electric field
distribution in the human chest cavity and in vivo
measurements of TTFields intensity within the lungs,
liver, and mediastinum of pigs. Intensity and distri-
bution of TTFields within the lung and mediastinum
were calculated using FEM simulations of the human
chest treated with transducer arrays positioned
anteroposteriorly (Figure 4A) or bilaterally
(Figure 4B). Despite the spread of the field in the
large nonuniform volume, the simulations demon-
strated that TTFields of sufficient intensity (2–4 V/
cm RMS) can be generated throughout the lungs and
mediastinum by applying 150-kHz alternating fieldsthrough noninvasive transducer arrays. The simula-
tions also demonstrated protection of hematopoietic
tissue through strong attenuation of TTFields by
vertebral and costal bony elements. Field intensity
was more than 10-fold lower in these regions than in
the lung parenchyma. In addition, field intensity was
30% higher in the mediastinum than in the lung
parenchyma. In vivo field measurements were per-
formed in the lungs, mediastinum, and liver of
anesthetized pigs to validate these simulations. The
measurements showed significant correlation with
the simulations, indicating that TTFields intensities
can be effectively generated within the lungs, liver,
and mediastinum (data not shown). Together, our
results suggest TTFields therapy can be effectively
delivered locally for the treatment of NSCLC.
In summary, the body of evidence from in vitro
studies, in vivo studies, and an early phase I/II
clinical trial in patients with advanced NSCLC,
suggest combining TTFields therapy with systemic
chemotherapy may be an approach that offers
enhanced efficacy, without incremental toxicity.
Further prospective studies to examine the optimal
combinations of therapy are warranted.REFERENCES
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